Prospect Capital Corp(PBC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PBC Prospect Capital Corp

退市 12-29 16:00:00 EST

25.06

+0.00

0.00%

最高25.06	最低25.06	成交量0.00
今开25.06	昨收25.06	日振幅0.00%
总市值92.18亿	流通市值0.00	总股本3.68亿
成交额31.97万	换手率--	流通股本0.00
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PBC","market":"US","secType":"STK","nameCN":"Prospect Capital Corp","latestPrice":25.06,"timestamp":1640811600000,"preClose":25.06,"halted":4,"volume":0,"delay":0,"floatShares":0,"shares":367817926,"eps":0.367626,"marketStatus":"退市","marketStatusCode":7,"change":0,"latestTime":"12-29 16:00:00 EST","open":25.06,"high":25.06,"low":25.06,"amount":319705.1613,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.367626,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732525200000},"adr":0,"adjPreClose":25.06,"adrRate":0,"dividendRate":0.028731,"volumeRatio":0},"requestUrl":"/m/hq/s/PBC","defaultTab":"news","newsList":[{"id":"2485261222","title":"Tharimmune, Inc.盘中异动 股价大跌5.75%报2.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485261222","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485261222?lang=zh_cn&edition=full","pubTime":"2024-11-22 22:47","pubTimestamp":1732286826,"startTime":"0","endTime":"0","summary":"北京时间2024年11月22日22时47分，Tharimmune, Inc.股票出现波动，股价大幅下挫5.75%。截至发稿，该股报2.46美元/股，成交量7981股，换手率0.54%，振幅3.83%。Tharimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.48%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，开发针对罕见免疫、炎症和肿瘤疾病的候选治疗药物组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122224706abd7992f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122224706abd7992f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRPX","BK4139","BK4007","THAR","PBC"],"gpt_icon":0},{"id":"2485049705","title":"Tharimmune, Inc.盘中异动 早盘大幅下挫5.60%报2.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485049705","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485049705?lang=zh_cn&edition=full","pubTime":"2024-11-21 22:31","pubTimestamp":1732199486,"startTime":"0","endTime":"0","summary":"北京时间2024年11月21日22时31分，Tharimmune, Inc.股票出现异动，股价急速跳水5.60%。截至发稿，该股报2.36美元/股，成交量3944股，换手率0.27%，振幅2.40%。Tharimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.22%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，开发针对罕见免疫、炎症和肿瘤疾病的候选治疗药物组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121223126abd4e62c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121223126abd4e62c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PBC","THAR"],"gpt_icon":0},{"id":"2484169121","title":"金十数据整理：每日美股市场要闻速递（11月20日 周三）","url":"https://stock-news.laohu8.com/highlight/detail?id=2484169121","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484169121?lang=zh_cn&edition=full","pubTime":"2024-11-20 21:29","pubTimestamp":1732109340,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["SY","2NVD.UK","NOK","III","INTC","TGT","NVDS","BK4114","IE0009G5SDU7.USD","SNVD.UK","LU0157215616.USD","LU0345770993.USD","TSLA","NIO.SI","0HAF.UK","IE00B19Z8X17.USD","GSK.UK","NVDD","IE0004086264.USD","IE0034235303.USD","TSLL","NVD2.UK","LU0289961442.SGD","3NVD.UK","LU0511384066.AUD","NVDS.UK","PBC","AAPL","NVDL","GSK","NVDY","LU2092627202.USD","LU1098665638.USD","NVD3.UK","ATHM","LU1935042991.SGD","LU0225283273.USD","IBAT","NVD","02518","LU0708995583.HKD","NVDA","EVS.SI","NVDU","YMM","NVDX","SMSN.UK","NIO","09866","LU0276348264.USD"],"gpt_icon":0},{"id":"2484211569","title":"葛兰素史克(GSK.US)IBAT抑制剂治疗PBC相关胆汁淤积性瘙痒III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2484211569","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484211569?lang=zh_cn&edition=full","pubTime":"2024-11-20 21:05","pubTimestamp":1732107905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月19日，葛兰素史克宣布III期GLISTEN研究取得了积极结果。该研究旨在评估回肠胆汁酸转运蛋白抑制剂Linerixibat治疗原发性胆汁性胆管炎相关的胆汁淤积性瘙痒成人患者的疗效和安全性。PBC是一种罕见的胆道疾病，主要影响女性，如果不进行治疗，可能导致肝脏损伤甚至肝衰竭。Linerixibat是一种口服的IBAT抑制剂，通过抑制胆汁酸的再摄取，旨在从根本上解决胆汁淤积性瘙痒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","IBAT","III","PBC","BK4588","BK4007","GSK.UK","GSK","BK4532","LU1829250122.USD","BK4134"],"gpt_icon":0},{"id":"2484667987","title":"Tharimmune, Inc.盘中异动 早盘快速上涨5.07%报2.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484667987","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484667987?lang=zh_cn&edition=full","pubTime":"2024-11-18 22:32","pubTimestamp":1731940333,"startTime":"0","endTime":"0","summary":"北京时间2024年11月18日22时32分，Tharimmune, Inc.股票出现异动，股价快速拉升5.07%。Tharimmune, Inc.股票所在的生物技术行业中，整体跌幅为0.30%。其相关个股中，Hcw Biologics Inc.、冠科美博、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Tharimmune, Inc.、Hcw Biologics Inc.、冠科美博较为活跃，换手率分别为516.39%、196.71%、186.34%，振幅较大的相关个股有Hcw Biologics Inc.、冠科美博、Biomx Inc.，振幅分别为46.50%、31.28%、19.34%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，开发针对罕见免疫、炎症和肿瘤疾病的候选治疗药物组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111822321395be485f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111822321395be485f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["THAR","BK4139","PBC"],"gpt_icon":0},{"id":"2483488432","title":"Tharimmune, Inc.盘中异动 早盘股价大跌5.12%报2.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483488432","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483488432?lang=zh_cn&edition=full","pubTime":"2024-11-13 22:33","pubTimestamp":1731508398,"startTime":"0","endTime":"0","summary":"北京时间2024年11月13日22时33分，Tharimmune, Inc.股票出现波动，股价急速下跌5.12%。截至发稿，该股报2.04美元/股，成交量97.7532万股，换手率85.09%，振幅1.40%。Tharimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.07%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，开发针对罕见免疫、炎症和肿瘤疾病的候选治疗药物组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113223318971a647d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113223318971a647d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PBC","BK4139","THAR"],"gpt_icon":0},{"id":"2481576660","title":"进博会成众多药品首秀“舞台”，医疗产业聚焦数智化","url":"https://stock-news.laohu8.com/highlight/detail?id=2481576660","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481576660?lang=zh_cn&edition=full","pubTime":"2024-11-05 18:58","pubTimestamp":1730804291,"startTime":"0","endTime":"0","summary":"今天，第七届中国国际进口博览会在国家会展中心（上海）正式开幕，包括默沙东、强生、拜耳、吉利德、碧迪医疗、波士顿科学在内的多家跨国企业携多款“进博首发、首展”展品亮相进博，涉及多个疾病领域，而在本届进博会上，数智化逐渐成为行业关注的焦点。多家跨国药企表示，进博会充满机遇，是众多新品首秀的“聚光灯”，促进各方合作的“催化剂”，也是企业发展的“助推器”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/243860","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["PBC"],"gpt_icon":0},{"id":"2480558042","title":"Zevia PBC   预计每股亏损8美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2480558042","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480558042?lang=zh_cn&edition=full","pubTime":"2024-11-04 23:44","pubTimestamp":1730735094,"startTime":"0","endTime":"0","summary":"   * Zevia PBC    将于11月6日公布截至2024年9月30日的财报，预计季度收入将出现下降。* 根据LSEG的数据，5位分析师的平均预期显示，这家总部位于加利福尼亚州恩西诺的公司的营收将从去年同期的4309万美元下降9.4%，至3903.6万美元。* LSEG 分析师对 Zevia PBC 的平均预期是每股亏损 8 美分。* 华尔街对 Zevia PBC 的 12 个月目标价中位数为 2.00 美元，高于上一次收盘价 1.16 美元。11月4日 - 以前季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBC","ZVIA"],"gpt_icon":0},{"id":"2480812472","title":"专访吉利德副总裁、中国总经理金方千：拥抱进博溢出效应，促进医疗创新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2480812472","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480812472?lang=zh_cn&edition=full","pubTime":"2024-11-02 14:22","pubTimestamp":1730528578,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛上海报道随着中国医疗改革的持续深入，创新药物的发展在中国迎来了黄金时期。中国的医药健康行业正翻开历史新篇章，从最初的医药创新追随者逐步转变为并行者，甚至在某些领域成为领跑者。在过去的数十年中，跨国制药企业通过共同建设，助力中国成为全球第二大医药医疗消费市场。它们为中国医药行业注入了资金、技术，并引入了新的市场结构与理念。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411023227121810.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411023227121810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PBC"],"gpt_icon":0},{"id":"2480889493","title":"Tharimmune, Inc.盘中异动 股价大跌5.61%报2.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480889493","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480889493?lang=zh_cn&edition=full","pubTime":"2024-11-01 21:30","pubTimestamp":1730467859,"startTime":"0","endTime":"0","summary":"北京时间2024年11月01日21时30分，Tharimmune, Inc.股票出现波动，股价快速下跌5.61%。截至发稿，该股报2.69美元/股，成交量2.1506万股，换手率1.87%，振幅0.00%。Tharimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，开发针对罕见免疫、炎症和肿瘤疾病的候选治疗药物组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101213059971a3d59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101213059971a3d59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["THAR","PBC","BK4139"],"gpt_icon":0},{"id":"2479038128","title":"Tharimmune, Inc.盘中异动 早盘急速下挫5.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479038128","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479038128?lang=zh_cn&edition=full","pubTime":"2024-10-31 21:31","pubTimestamp":1730381463,"startTime":"0","endTime":"0","summary":"北京时间2024年10月31日21时31分，Tharimmune, Inc.股票出现异动，股价急速跳水5.68%。Tharimmune, Inc.股票所在的生物技术行业中，整体跌幅为1.28%。其相关个股中，Aerovate Therapeutics, Inc.、Evogene Ltd.、Day One Biopharmaceuticals, Inc.涨幅较大，Evogene Ltd.、Aditxt, Inc.、Palisade Bio, Inc.较为活跃，换手率分别为188.48%、184.24%、144.61%，振幅较大的相关个股有Equillium, Inc.、Enanta Pharmaceuticals, Inc.、Aerovate Therapeutics, Inc.，振幅分别为12.32%、6.96%、5.48%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，开发针对罕见免疫、炎症和肿瘤疾病的候选治疗药物组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031213103ab8b7f97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031213103ab8b7f97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PBC","BK4139","THAR"],"gpt_icon":0},{"id":"2479788935","title":"Tharimmune, Inc.盘中异动 早盘快速拉升181.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479788935","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479788935?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:30","pubTimestamp":1730295005,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日21时30分，Tharimmune, Inc.股票出现异动，股价快速拉升181.28%。Tharimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Renovorx, Inc.、Newamsterdam Pharma Company N.V.、Zymeworks Inc.涨幅较大，Tharimmune, Inc.、Ensysce Biosciences, Inc.、Gri Bio, Inc.较为活跃，换手率分别为1587.33%、91.57%、13.62%，振幅较大的相关个股有Tempest Therapeutics, Inc.、Zymeworks Inc.、Zyversa Therapeutics, Inc.，振幅分别为0.70%、0.00%、0.00%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，开发针对罕见免疫、炎症和肿瘤疾病的候选治疗药物组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030213005a1faccd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030213005a1faccd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["THAR","BK4139","PBC"],"gpt_icon":0},{"id":"2478642539","title":"相约进博｜多家药企携“明星产品”、“黑科技”赴“进博之约”，助推诊疗革新","url":"https://stock-news.laohu8.com/highlight/detail?id=2478642539","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478642539?lang=zh_cn&edition=full","pubTime":"2024-10-26 04:56","pubTimestamp":1729889776,"startTime":"0","endTime":"0","summary":"蓝鲸新闻10月25日讯 第七届中国国际进口博览会将于11月5日-10日在上海举办。按照往年情况，医疗器械及医药保健展区一直是“最火爆”也是“最卷”的展区之一。而其另一款“明星产品”、黑科技Ion支气管镜机器人将迎来国内获批上市后的进博首秀。据悉，吉利德已向中国药品审评部门递交了Lenacapavir用于HIV治疗的上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/243069","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["PBC","DBS"],"gpt_icon":0},{"id":"2474721382","title":"大模型太“烧钱”！OpenAI预计2026年将亏损140亿美元，2029年才能盈利，财务重压之下拟转向全新公司结构","url":"https://stock-news.laohu8.com/highlight/detail?id=2474721382","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474721382?lang=zh_cn&edition=full","pubTime":"2024-10-10 19:27","pubTimestamp":1728559643,"startTime":"0","endTime":"0","summary":"每经记者：郑雨航 每经实习记者：岳楚鹏    每经编辑：兰素英图片来源：视觉中国-VCG31N2008743681AI领域的领军者OpenAI正在面临着前所未有的挑战。当地时间10月9日，据外媒报道，尽管在最新一轮66亿美元的融资中，OpenAI的估值达到1570亿美元，但公司仍需应对高达数十亿美元的年度亏损，以及未来几年巨额的运营成本。...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/ONAHr6WHJEAi2-BGNZlnnPCMlxV2_GAzQzbt274QRws6cAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/ONAHr6WHJEAi2-BGNZlnnPCMlxV2_GAzQzbt274QRws6cAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241010A08LAE00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241010A08LAE00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["PBC"],"gpt_icon":0},{"id":"2474763632","title":"英媒：OpenAI计划采用公益企业结构以抵御敌意收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2474763632","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474763632?lang=zh_cn&edition=full","pubTime":"2024-10-10 00:34","pubTimestamp":1728491681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4588","IE00BJLML261.HKD","IE00BFSS7M15.SGD","GB00B4LPDJ14.GBP","IE0005OL40V9.USD","IE00BJTD4N35.SGD","IE00B1BXHZ80.USD","IE00B3S45H60.SGD","GB00B4QBRK32.GBP","IE0004086264.USD","BK4566","BK4579","IE00B7KXQ091.USD","BK4576","BK4525","IE0009G5SDU7.USD","MSFT","IE00BK4W5L77.USD","IE0003U64NQ7.SGD","BK4567","IE00BKDWB100.SGD","IE00B19Z9505.USD","BK4592","BK4516","161631","IE0009356076.USD","IE00B5TLWC47.USD","BK4097","IE00BFSS8Q28.SGD","IE000KEQY171.SGD","IE00BDRTCR15.USD","IE00BK4W5M84.HKD","IE00B3SWFQ91.USD","BK4503","IE00BKPKM429.USD","IE00B775H168.HKD","IE000W1ABFV2.USD","PBC","BK4577","IE00B1XK9C88.USD","BK4587","IE0004445239.USD","BK4585","BK4528","BK4550","IE00BLSP4239.USD","IE0034235303.USD","IE00B4YYXB79.USD","IE00BBT3K403.USD"],"gpt_icon":0},{"id":"2474114408","title":"Tharimmune, Inc.盘中异动 股价大涨5.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2474114408","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474114408?lang=zh_cn&edition=full","pubTime":"2024-10-09 00:16","pubTimestamp":1728404160,"startTime":"0","endTime":"0","summary":"北京时间2024年10月09日00时16分，Tharimmune, Inc.股票出现波动，股价大幅上涨5.98%。截至发稿，该股报2.03美元/股，成交量1.8837万股，换手率1.64%，振幅7.31%。Tharimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，开发针对罕见免疫、炎症和肿瘤疾病的候选治疗药物组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410090016009719f033&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410090016009719f033&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["THAR","BK4139","PBC"],"gpt_icon":0},{"id":"2471383193","title":"Tharimmune, Inc.盘中异动 早盘急速拉升6.12%报2.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2471383193","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471383193?lang=zh_cn&edition=full","pubTime":"2024-09-30 21:31","pubTimestamp":1727703074,"startTime":"0","endTime":"0","summary":"北京时间2024年09月30日21时31分，Tharimmune, Inc.股票出现波动，股价大幅上涨6.12%。截至发稿，该股报2.60美元/股，成交量5.3178万股，换手率4.63%，振幅0.00%。Tharimmune, Inc.股票所在的生物技术行业中，整体跌幅为0.31%。Tharimmune, Inc.公司简介：Tharimmune Inc 是一家生物技术公司，开发针对罕见免疫、炎症和肿瘤疾病的候选治疗药物组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930213118ab672717&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930213118ab672717&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PBC","BK4139","THAR"],"gpt_icon":0},{"id":"2466868422","title":"FDA 工作人员对 Intercept 公司肝病药物的疗效表示担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2466868422","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466868422?lang=zh_cn&edition=full","pubTime":"2024-09-11 20:38","pubTimestamp":1726058289,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透9月11日 - 美国食品和药物管理局的工作人员周三对Intercept制药公司正在等待传统批准的肝病药物的疗效提出了担忧。      审查人员在FDA网站上公布的简报文件中说，该药的确证试验没有提供证据证明它对一种名为原发性胆汁性胆管炎的罕见疾病患者有效(PBC)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBC"],"gpt_icon":0},{"id":"2466303920","title":"这两天硅谷炸锅了，每个人都在讨论这个词：创始人模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2466303920","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466303920?lang=zh_cn&edition=full","pubTime":"2024-09-08 22:00","pubTimestamp":1725804000,"startTime":"0","endTime":"0","summary":"文章一经发布便很快在硅谷发酵，引发了创始人们的强烈共鸣。然而，在Graham发表这篇文章之后，“创始人模式”的呼声在硅谷逐渐壮大。爱彼迎曾在疫情时期遭遇重创，并一度退出中国市场，作为留在公司的唯一一个联合创始人，Chesky领导了一轮大规模裁员，重新调整公司业务重点，试图将爱彼迎拉出泥潭。当然，创始人模式也存在一些明显的失败案例。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656034198&idx=2&sn=d75d90e93a019344a52fac58cab39826&chksm=67d9e1c6626d1b35e024e6729278a01b933f5e50424076f42aa86c9c44fec2406938083ed875&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["2NVD.UK","MSFT","ABNB","LU1551013425.SGD","BK4514","LU2756315664.SGD","LU2249611893.SGD","IE0004445239.USD","L","BK4538","TSLA","SG9999015978.USD","IE00BJJMRX11.SGD","HK0000320223.HKD","BK4511","IE0034235188.USD","IE00BYXW3230.USD","IE0034235303.USD","GOOG","LU0724617625.USD","LU0061474960.USD","BK4099","BK4535","LU1551013342.USD","3NVD.UK","SBUX","LU0211327993.USD","PBC","AAPL","LU2357305700.SGD","IE00B7KXQ091.USD","HK0000320264.USD","LU0079474960.USD","LU0082616367.USD","LU1861559042.SGD","IE00BBT3K403.USD","LU0053666078.USD","IE0004445015.USD","IE00BKDWB100.SGD","LU1914381329.SGD","BK4533","NVDA","GOOGL","GB00BDT5M118.USD","META","BK4515","BK4534","BK4512","BK4532","IE00BLSP4239.USD","IE00BJLML261.HKD","IE00B19Z9505.USD","IE00B775H168.HKD"],"gpt_icon":1},{"id":"2465792503","title":"Planet Labs PBC 公布截至 7 月 31 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2465792503","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465792503?lang=zh_cn&edition=full","pubTime":"2024-09-06 05:01","pubTimestamp":1725570088,"startTime":"0","endTime":"0","summary":"   * Planet Labs PBC   报告，截至7月31日的季度调整后每股亏损6美分，高于去年同期的每股-7美分。十位分析师对该季度的平均预期是每股亏损 6 美分。* 营收同比增长 13.6%，达到 6109 万美元；分析师预期为 6182 万美元。* Planet Labs PBC 公布的本季度每股收益为亏损 13 美分。* 该公司当季亏损 3867 万美元。* Planet Labs PBC 的股价本季度上涨了 33.3%，今年迄今为止上涨了 0.4%。华尔街对 Planet Labs PBC 的 12 个月目标价中位数为 4.03 美元。本摘要由 LSEG 9 月 5 日 09:00 p.m. UTC 调制解调器器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4123","PBC","PL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.prospectstreet.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Prospect Capital Corporation成立于2004年4月13日，是一家封闭式投资公司。公司是一家金融服务公司，主要向中等市场的私人控股公司提供贷款和投资。公司是一家在马里兰州注册成立的封闭式投资公司。其投资目标是通过债务和股权投资实现当期收益和长期资本增值。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.034529},{"month":2,"riseRate":0,"avgChangeRate":-0.031267},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.060348},{"month":4,"riseRate":1,"avgChangeRate":0.067548},{"month":5,"riseRate":0.333333,"avgChangeRate":0.002978},{"month":6,"riseRate":0.666667,"avgChangeRate":0.011102},{"month":7,"riseRate":0.666667,"avgChangeRate":0.009468},{"month":8,"riseRate":0.666667,"avgChangeRate":0.011194},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.002421},{"month":10,"riseRate":0.666667,"avgChangeRate":0.00649},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.002162},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.003597}],"exchange":"NYSE","name":"Prospect Capital Corp","nameEN":"Prospect Capital Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Prospect Capital Corp(PBC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Prospect Capital Corp(PBC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Prospect Capital Corp,PBC,Prospect Capital Corp股票,Prospect Capital Corp股票老虎,Prospect Capital Corp股票老虎国际,Prospect Capital Corp行情,Prospect Capital Corp股票行情,Prospect Capital Corp股价,Prospect Capital Corp股市,Prospect Capital Corp股票价格,Prospect Capital Corp股票交易,Prospect Capital Corp股票购买,Prospect Capital Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Prospect Capital Corp(PBC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Prospect Capital Corp(PBC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}